+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PCSK9 Targeted Drugs Market - Global Forecast 2026-2032- Product Image
PCSK9 Targeted Drugs Market - Global Forecast 2026-2032- Product Image
Sale

PCSK9 Targeted Drugs Market - Global Forecast 2026-2032

  • Report

  • 195 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6135130
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The PCSK9 Targeted Drugs Market is projected to reach USD 9.92 Billion in 2026. It is expected to continue growing at a CAGR of 9.53%, reaching USD 17.12 Billion by 2032.

PCSK9-Targeted Drugs: Executive Overview

PCSK9-targeted drugs represent an established approach to lowering low-density lipoprotein cholesterol (LDL-C) for patients who require additional treatment beyond lifestyle changes and conventional lipid-lowering therapy. The category includes monoclonal antibodies and other approaches designed to reduce PCSK9 activity or expression, supporting greater hepatic clearance of circulating LDL-C. Clinical use is shaped by cardiovascular-risk assessment, treatment guidelines, prior therapy, adherence, administration requirements, and access conditions.

Treatment Pathways Are Shifting Toward Earlier Risk Management

The treatment landscape is moving toward more individualized lipid management, with greater attention to cumulative exposure to elevated LDL-C and the need for sustained risk reduction. PCSK9-targeted options are increasingly considered when patients have familial hypercholesterolemia, established atherosclerotic cardiovascular disease, or inadequate response or tolerance to other therapies. Practical factors-including injection frequency, persistence, monitoring, prior authorization, and integration with primary and specialty care-are becoming as important as pharmacologic efficacy in determining real-world use.

Artificial Intelligence Strengthens Patient Identification and Care Coordination

Artificial intelligence can support PCSK9-targeted drug pathways by identifying patients with persistently elevated LDL-C, probable familial hypercholesterolemia, or high cardiovascular risk from longitudinal clinical records. Predictive tools may help prioritize testing, flag treatment gaps, personalize follow-up, and identify adherence risks. However, clinical validation, transparent decision logic, privacy safeguards, bias monitoring, and clinician oversight are essential before algorithmic outputs influence prescribing or coverage decisions.

Regional Differences Reflect Guidelines, Access, and Health-System Capacity

North America is characterized by advanced specialty-care infrastructure and strong emphasis on outcomes-based lipid management, although affordability and authorization processes can affect access. Europe combines mature cardiovascular guidelines with country-level variation in reimbursement, diagnostic pathways, and specialist capacity. Asia-Pacific presents substantial diversity, ranging from sophisticated urban cardiology services to uneven access in rural areas, with growing attention to familial hypercholesterolemia and prevention. Latin America faces differences in screening, affordability, and continuity of care. The Middle East is supported by expanding private and public healthcare capacity but varies widely in coverage and specialist access. Africa has significant unmet needs related to diagnosis, laboratory availability, treatment affordability, and long-term cardiovascular-risk management.

Economic and Security Groups Shape Adoption Conditions

ASEAN markets differ in reimbursement structures, healthcare maturity, and access to lipid specialists, making regional coordination and locally appropriate diagnostic pathways important. BRICS countries combine large patient populations with varied public-health priorities, domestic manufacturing capabilities, and uneven access to advanced therapies. The European Union benefits from shared scientific and regulatory frameworks but retains national differences in health-technology assessment and reimbursement. G7 members generally have strong clinical infrastructure and data capabilities, while cost-effectiveness requirements and budget management influence utilization. GCC countries often possess well-resourced healthcare systems but face variation in prevention programs and reliance on imported therapies. NATO members span diverse health systems, creating differences in procurement, guideline implementation, and cardiovascular-care capacity.

Country Priorities Vary Across Diagnosis, Reimbursement, and Delivery

Australia and Canada combine robust clinical systems with geographic access challenges and structured reimbursement decisions. Brazil and Mexico face substantial variation between urban and rural care, alongside affordability and diagnostic gaps. China and India are expanding cardiovascular services while managing differences in regional capacity, out-of-pocket exposure, and specialist availability. Japan, South Korea, France, Germany, Italy, Spain, and the United Kingdom have established lipid-management expertise, with national differences in prescribing criteria, care pathways, and reimbursement administration. Russia’s cardiovascular disease burden creates a need for stronger prevention and continuity of care, while access conditions and health-system constraints influence the deployment of advanced therapies. Across these countries, familial hypercholesterolemia detection, treatment persistence, and equitable access remain central priorities.

Industry Leaders Should Align Evidence, Access, and Patient Support

Leaders should develop evidence packages that connect LDL-C reduction with clinically meaningful cardiovascular outcomes, patient subgroups, persistence, and real-world health-system value. They should simplify initiation and renewal processes, strengthen diagnostic networks for familial hypercholesterolemia, and design patient-support services around injection training, reminders, affordability navigation, and follow-up. Partnerships with clinicians, payers, laboratories, and public-health programs can improve appropriate identification and continuity of care. Organizations deploying artificial intelligence should establish governance covering validation, explainability, data quality, cybersecurity, and human accountability.

Methodology Combines Clinical, Policy, and Health-System Evidence

This executive summary uses a structured synthesis of authoritative clinical guidance, peer-reviewed evidence, regulatory and reimbursement documentation, health-system publications, and publicly available information on cardiovascular-risk management. Analysis is organized by treatment evolution, artificial-intelligence applications, region, economic grouping, and country context. Findings are interpreted qualitatively, with attention to clinical eligibility, diagnostic capacity, administration, adherence, affordability, reimbursement, and system readiness. No market estimates, market shares, forecasts, or company-specific claims are used.

PCSK9-Targeted Drugs Require Integrated, Equity-Focused Execution

The strategic importance of PCSK9-targeted drugs depends not only on their pharmacologic role but also on how effectively health systems identify eligible patients, sustain treatment, and manage access. Progress will come from coordinated cardiovascular prevention, better familial-hypercholesterolemia detection, reliable follow-up, evidence-based reimbursement, and responsible use of digital and artificial-intelligence tools. Industry and healthcare leaders that connect clinical value with practical delivery can improve the consistency and equity of LDL-C management across diverse populations.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. PCSK9 Targeted Drugs Market, by Drug Class
7.1. Introduction
7.2. Monoclonal Antibody
7.2.1. Alirocumab
7.2.2. Evolocumab
7.3. SiRNA
8. PCSK9 Targeted Drugs Market, by Indication
8.1. Introduction
8.2. Atherosclerotic Cardiovascular Disease
8.3. Heterozygous Familial Hypercholesterolemia
8.4. Homozygous Familial Hypercholesterolemia
9. PCSK9 Targeted Drugs Market, by End User
9.1. Introduction
9.2. Clinics
9.3. Hospitals
9.4. Specialty Centers
10. PCSK9 Targeted Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Offline Pharmacy
10.3. Online Pharmacy
11. PCSK9 Targeted Drugs Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. PCSK9 Targeted Drugs Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. PCSK9 Targeted Drugs Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Akeso, Inc.
15.2. Alnylam Pharmaceuticals, Inc.
15.3. Amgen Inc.
15.4. Arrowhead Pharmaceuticals, Inc.
15.5. AstraZeneca PLC
15.6. Bristol-Myers Squibb Company
15.7. Eli Lilly and Company
15.8. F. Hoffmann-La Roche Ltd.
15.9. Innovent Biologics, Inc.
15.10. Ionis Pharmaceuticals, Inc.
15.11. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
15.12. LIB Therapeutics, LLC
15.13. Merck & Co., Inc.
15.14. Novartis AG
15.15. Pfizer Inc.
15.16. Regeneron Pharmaceuticals, Inc.
15.17. Sanofi S.A.
15.18. Shanghai Junshi Biosciences Co., Ltd.
15.19. Silence Therapeutics PLC
15.20. Verve Therapeutics, Inc.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global PCSK9 Targeted Drugs Market, Years Considered for the Study
FIGURE 2. Global PCSK9 Targeted Drugs Market, Research Design
FIGURE 3. Global PCSK9 Targeted Drugs Market, Research Framework
FIGURE 4. Global PCSK9 Targeted Drugs Market, Data Triangulation
FIGURE 5. Global PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global PCSK9 Targeted Drugs Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global PCSK9 Targeted Drugs Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global PCSK9 Targeted Drugs Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 9. Global PCSK9 Targeted Drugs Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global PCSK9 Targeted Drugs Market Size, by End User, 2025 vs 2032 (%)
FIGURE 11. Global PCSK9 Targeted Drugs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global PCSK9 Targeted Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global PCSK9 Targeted Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global PCSK9 Targeted Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global PCSK9 Targeted Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global PCSK9 Targeted Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global PCSK9 Targeted Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global PCSK9 Targeted Drugs Market Segmentation & Coverage
TABLE 2. Global PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global Monoclonal Antibody Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Monoclonal Antibody Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Monoclonal Antibody Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Alirocumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Alirocumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Alirocumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Evolocumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Evolocumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Evolocumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global SiRNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global SiRNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global SiRNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 17. Global Atherosclerotic Cardiovascular Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Atherosclerotic Cardiovascular Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Atherosclerotic Cardiovascular Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Heterozygous Familial Hypercholesterolemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Heterozygous Familial Hypercholesterolemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Heterozygous Familial Hypercholesterolemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Homozygous Familial Hypercholesterolemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Homozygous Familial Hypercholesterolemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Homozygous Familial Hypercholesterolemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 27. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Specialty Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Specialty Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Specialty Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 37. Global Offline Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Offline Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Offline Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global PCSK9 Targeted Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Asia-Pacific PCSK9 Targeted Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Asia-Pacific PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 46. Asia-Pacific PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 47. Asia-Pacific PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 48. Asia-Pacific PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 49. Asia-Pacific PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 50. North America PCSK9 Targeted Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. North America PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 52. North America PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 53. North America PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 54. North America PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 55. North America PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 56. Latin America PCSK9 Targeted Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Latin America PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 58. Latin America PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 59. Latin America PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 60. Latin America PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 61. Latin America PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 62. Europe PCSK9 Targeted Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Europe PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 64. Europe PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 65. Europe PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 66. Europe PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 67. Europe PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 68. Middle East PCSK9 Targeted Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Middle East PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 70. Middle East PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 71. Middle East PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 72. Middle East PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 73. Middle East PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 74. Africa PCSK9 Targeted Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Africa PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 76. Africa PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 77. Africa PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 78. Africa PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 79. Africa PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 80. Global PCSK9 Targeted Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. ASEAN PCSK9 Targeted Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. ASEAN PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 83. ASEAN PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 84. ASEAN PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 85. ASEAN PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 86. ASEAN PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 87. GCC PCSK9 Targeted Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. GCC PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 89. GCC PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 90. GCC PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 91. GCC PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 92. GCC PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 93. European Union PCSK9 Targeted Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. European Union PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 95. European Union PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 96. European Union PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 97. European Union PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 98. European Union PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 99. BRICS PCSK9 Targeted Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. BRICS PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 101. BRICS PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 102. BRICS PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 103. BRICS PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 104. BRICS PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 105. G7 PCSK9 Targeted Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. G7 PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 107. G7 PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 108. G7 PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 109. G7 PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 110. G7 PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 111. NATO PCSK9 Targeted Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. NATO PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 113. NATO PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 114. NATO PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 115. NATO PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 116. NATO PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. Global PCSK9 Targeted Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 118. United States PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
TABLE 119. United States PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 120. United States PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 121. United States PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 122. United States PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 123. United States PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 124. Canada PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
TABLE 125. Canada PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 126. Canada PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 127. Canada PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 128. Canada PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 129. Canada PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 130. Mexico PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
TABLE 131. Mexico PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 132. Mexico PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 133. Mexico PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 134. Mexico PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. Mexico PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 136. Brazil PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
TABLE 137. Brazil PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 138. Brazil PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 139. Brazil PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 140. Brazil PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 141. Brazil PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 142. United Kingdom PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
TABLE 143. United Kingdom PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 144. United Kingdom PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 145. United Kingdom PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 146. United Kingdom PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 147. United Kingdom PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 148. Germany PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
TABLE 149. Germany PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 150. Germany PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 151. Germany PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 152. Germany PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 153. Germany PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 154. France PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
TABLE 155. France PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 156. France PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 157. France PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 158. France PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 159. France PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 160. Russia PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
TABLE 161. Russia PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 162. Russia PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 163. Russia PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 164. Russia PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 165. Russia PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 166. Italy PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
TABLE 167. Italy PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 168. Italy PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 169. Italy PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 170. Italy PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 171. Italy PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 172. Spain PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
TABLE 173. Spain PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 174. Spain PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 175. Spain PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 176. Spain PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 177. Spain PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 178. China PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
TABLE 179. China PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 180. China PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 181. China PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 182. China PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 183. China PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 184. India PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
TABLE 185. India PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 186. India PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 187. India PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 188. India PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 189. India PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 190. Japan PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
TABLE 191. Japan PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 192. Japan PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 193. Japan PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 194. Japan PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 195. Japan PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 196. Australia PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
TABLE 197. Australia PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 198. Australia PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 199. Australia PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 200. Australia PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 201. Australia PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 202. South Korea PCSK9 Targeted Drugs Market Size, 2017-2032 (USD Million)
TABLE 203. South Korea PCSK9 Targeted Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 204. South Korea PCSK9 Targeted Drugs Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 205. South Korea PCSK9 Targeted Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 206. South Korea PCSK9 Targeted Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 207. South Korea PCSK9 Targeted Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 208. Global PCSK9 Targeted Drugs Market Share, by Key Player, 2025
TABLE 209. Global PCSK9 Targeted Drugs Market, Key Experts

Companies Mentioned

  • Akeso, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Innovent Biologics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • LIB Therapeutics, LLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Shanghai Junshi Biosciences Co., Ltd.
  • Silence Therapeutics PLC
  • Verve Therapeutics, Inc.

Related Topics

Related Reports

PCSK9 Inhibitor Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2026 To 2034 - Product Image

PCSK9 Inhibitor Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2026 To 2034

  • Report
  • 179 Pages
  • Global
From
Cholesterol Lowering Drug Market - Global Forecast 2026-2032 - Product Image

Cholesterol Lowering Drug Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
PCSK9 Inhibitor Market Report 2026 - Product Image

PCSK9 Inhibitor Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Hyperlipidemia Drugs Market - Global Forecast 2026-2032 - Product Image

Hyperlipidemia Drugs Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
PCSK9 Inhibitor Market Outlook 2026-2034: Market Share, and Growth Analysis by Drug Type (Monoclonal Antibodies, RNA-interference Therapeutics, Small-Molecule/Oral PCSK9 Inhibitors), Route of Administration, Indication, Distribution Channel - Product Image

PCSK9 Inhibitor Market Outlook 2026-2034: Market Share, and Growth Analysis by Drug Type (Monoclonal Antibodies, RNA-interference Therapeutics, Small-Molecule/Oral PCSK9 Inhibitors), Route of Administration, Indication, Distribution Channel

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.